ProQR Therapeutics PRQR Stock
ProQR Therapeutics Price Chart
ProQR Therapeutics PRQR Financial and Trading Overview
| ProQR Therapeutics stock price | 1.41 USD |
| Previous Close | 1.36 USD |
| Open | 1.39 USD |
| Bid | 1.01 USD x 200 |
| Ask | 1.76 USD x 200 |
| Day's Range | 1.37 - 1.44 USD |
| 52 Week Range | 1.2 - 2.49 USD |
| Volume | 568.54K USD |
| Avg. Volume | 825.14K USD |
| Market Cap | 199.27M USD |
| Beta (5Y Monthly) | 0.271 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.67 USD |
PRQR Valuation Measures
| Enterprise Value | 90.11M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.0453563 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 10.8166275 |
| Price/Book (mrq) | 2.2293003 |
| Enterprise Value/Revenue | 4.891 |
| Enterprise Value/EBITDA | -2.151 |
Trading Information
ProQR Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.271 |
| 52-Week Change | -37.32% |
| S&P500 52-Week Change | 12.28% |
| 52 Week High | 2.49 USD |
| 52 Week Low | 1.2 USD |
| 50-Day Moving Average | 1.59 USD |
| 200-Day Moving Average | 1.68 USD |
PRQR Share Statistics
| Avg. Volume (3 month) | 825.14K USD |
| Avg. Daily Volume (10-Days) | 589.38K USD |
| Shares Outstanding | 141.33M |
| Float | 91.44M |
| Short Ratio | 2.96 |
| % Held by Insiders | 17.45% |
| % Held by Institutions | 55.27% |
| Shares Short | 2.89M |
| Short % of Float | 2.70% |
| Short % of Shares Outstanding | 2.04% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -228.17% |
| Operating Margin (ttm) | -232.60% |
| Gross Margin | 100.00% |
| EBITDA Margin | -227.44% |
Management Effectiveness
| Return on Assets (ttm) | -19.75% |
| Return on Equity (ttm) | -57.40% |
Income Statement
| Revenue (ttm) | 18.42M USD |
| Revenue Per Share (ttm) | 0.17 USD |
| Quarterly Revenue Growth (yoy) | 120.39% |
| Gross Profit (ttm) | 18.42M USD |
| EBITDA | -41902000 USD |
| Net Income Avi to Common (ttm) | -42037000 USD |
| Diluted EPS (ttm) | -0.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 117.13M USD |
| Total Cash Per Share (mrq) | 0.83 USD |
| Total Debt (mrq) | 15.31M USD |
| Total Debt/Equity (mrq) | 19.27 USD |
| Current Ratio (mrq) | 3.488 |
| Book Value Per Share (mrq) | 0.63248545 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -49007000 USD |
| Levered Free Cash Flow (ttm) | -19073124 USD |
Profile of ProQR Therapeutics
| Country | United States |
| State | N/A |
| City | Leiden |
| Address | Zernikedreef 9 |
| ZIP | 2333 CK |
| Phone | 31 88 166 7000 |
| Website | https://www.proqr.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 186 |
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Q&A For ProQR Therapeutics Stock
What is a current PRQR stock price?
ProQR Therapeutics PRQR stock price today per share is 1.41 USD.
How to purchase ProQR Therapeutics stock?
You can buy PRQR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ProQR Therapeutics?
The stock symbol or ticker of ProQR Therapeutics is PRQR.
Which industry does the ProQR Therapeutics company belong to?
The ProQR Therapeutics industry is Biotechnology.
How many shares does ProQR Therapeutics have in circulation?
The max supply of ProQR Therapeutics shares is 141.33M.
What is ProQR Therapeutics Price to Earnings Ratio (PE Ratio)?
ProQR Therapeutics PE Ratio is now.
What was ProQR Therapeutics earnings per share over the trailing 12 months (TTM)?
ProQR Therapeutics EPS is -0.45 USD over the trailing 12 months.
Which sector does the ProQR Therapeutics company belong to?
The ProQR Therapeutics sector is Healthcare.
ProQR Therapeutics PRQR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25136.27 USD — |
-0.91
|
7.74B USD — | 24872.41 USD — | 25423.09 USD — | — - | 7.74B USD — |
|
US Tech Global Market Composite
NQGM
US
|
1937.83 USD — |
-1.05
|
— — | 1915.46 USD — | 1955.74 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7211.27 USD — |
-0.5
|
— — | 7149.19 USD — | 7238.9 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.29 USD — |
-0.34
|
— — | 1358.68 USD — | 1373.65 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31061.46 USD — |
-0.9
|
— — | 30735.41 USD — | 31415.87 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
